Amanta Healthcare IPO 2025: dates, price band, listing

What the IPO was and why it mattered

Amanta Healthcare Limited, an Ahmedabad-based pharmaceutical company focused on sterile liquid formulations and medical devices, came to the main board with a book-built IPO. The issue size was stated as ₹126 crore and was entirely a fresh issue, meaning there was no offer for sale. The IPO was positioned as an expansion funding event, with the company outlining capital expenditure plans for additional manufacturing lines at its facility in Hariyala, Kheda, Gujarat. The price band was set at ₹120 to ₹126 per share, with the issue price finalised at ₹126 per share. Shares were listed on both BSE and NSE, expanding access for a broader investor base.

IPO timeline: open, close, allotment and listing

The IPO opened for subscription on Monday, September 1, 2025 and closed on Wednesday, September 3, 2025. Basis of allotment was finalised on Thursday, September 4, 2025. The credit of shares to demat accounts was indicated for Monday, September 8, 2025, with refunds also initiated on September 8, 2025 in the provided timeline. The shares listed on Tuesday, September 9, 2025 on BSE and NSE. The anchor bid date was August 29, 2025, and the issue raised ₹37.80 crore from anchor investors.

Issue structure, size and key terms

The IPO was described as a main-board, bookbuilding issue aggregating up to ₹126 crore. One set of details specified the total issue size as 1,00,00,000 equity shares of face value ₹10 each. The issue was also described in one place as “70 lakh equity shares”, but the repeated issue-size table and main IPO details stated 1,00,00,000 shares aggregating up to ₹126 crore, and the article’s numbers largely align to that figure.

The pre-IPO market capitalisation was stated at ₹489.25 crore. The BSE script code and NSE symbol were given as 544502 and AMANTA, respectively. The sale type was fresh capital.

Price band, lot size and retail investment

The price band was ₹120 to ₹126 per share, with the final issue price at ₹126 per share. The lot size was 119 shares, and bids could be placed in multiples of 119. The minimum retail investment at the upper end of the price band was stated as ₹14,994 for 1 lot (119 shares). A separate minimum investment figure of ₹14,280 for 119 shares also appeared in the provided data, but the cutoff-based retail figure repeatedly cited was ₹14,994.

For non-institutional investors (NII), the sNII minimum application was 14 lots (1,666 shares) for ₹2,09,916. The bNII minimum was 67 lots (7,973 shares) for ₹10,04,598. A “Retail (Max)” example was also provided at 13 lots (1,547 shares) for ₹1,94,922.

Allocation and investor categories

The allocation framework provided indicated:

• QIB portion not more than 50% of the offer
• Retail portion not less than 35% of the offer
• NII portion not less than 15% of the offer

A separate line item in the data also referenced anchor investors with 30,00,000 shares (30.00%) and mentioned QIB 50,00,000 shares (50.00%), retail 35,00,000 shares (35.00%), and NII 15,00,000 shares (15.00%). The text also included a confusing “QIB (Ex-Anchor)” line, but the broader split across QIB, retail, and NII was consistently presented around the standard 50-35-15 structure.

Anchor book and lock-in dates

The issue raised ₹37.80 crore from anchor investors, with the anchor bid date stated as August 29, 2025. The anchor lock-in schedule provided was:

• 50% shares lock-in end (30 days): Friday, October 3, 2025
• Remaining shares lock-in end (90 days): Tuesday, December 2, 2025

Use of proceeds: where the money was planned to go

The stated objects of the issue centred on capacity creation at the Hariyala, Kheda facility in Gujarat. The data included a capex plan of ₹70.00 crore for civil construction and equipment, plant and machinery to set up a new SteriPort manufacturing line. Another table stated ₹30.133 crore for setting up a new manufacturing line for SVP at the same location. General corporate purposes were also listed, with the amount to be finalised.

Business snapshot: what Amanta Healthcare does

Incorporated in December 1994, Amanta Healthcare develops, manufactures and markets sterile liquid products, specifically parenteral products. These are packaged in plastic containers using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. The company also manufactures medical devices. The product mention in the provided text includes IV fluids, diluents, ophthalmic, respiratory care and irrigation solutions, and medical device offerings such as irrigation solutions, first aid solutions and eye lubricants.

Financial performance cited in the provided data

The provided information included FY2024 revenue and profitability and a comparison to the previous year. FY24 revenue was stated as INR 2.803 billion, up 8.2% from INR 2.591 billion in FY23. Normalised to ₹ crore, that is ₹280.3 crore in FY24 versus ₹259.1 crore in FY23. Net profit in FY24 was stated as INR 36.2 million (₹3.62 crore), compared with a loss of INR 21.1 million (₹2.11 crore loss) in the previous fiscal year.

Subscription and demand: how the book was received

As of September 3, 2025, 4:01 PM, subscription figures were reported as:

• QIB: 16.81x
• NII: 185.14x
• Retail: 48.73x
• Total: 68.84x

Another line in the provided data also stated that the IPO “was subscribed 82.60 times.” Since both numbers are present in the dataset, they should be read as values reported by different sources or at different cut-off times.

Listing outcome and post-listing price references

The listing detail table in the data showed a BSE listing at ₹135.00 against the issue price of ₹126.00, implying a listing gain of ₹9.00, or 7.14%. Separately, a “Price Summary” snapshot (dated 13-Mar-2026, 3:30 PM) showed a last closing price of ₹96.25, with a 52-week high of ₹154.40 and a 52-week low of ₹93.30. The dataset also contained different “current market price” references such as ₹103.24 and ₹126.96, indicating updates captured at different times.

Key IPO facts at a glance

Market impact and what investors tracked

The book showed particularly high interest in the NII segment based on the reported 185.14x subscription, while retail was also strong at 48.73x. The QIB subscription was reported at 16.81x in the provided cut-off data. The stock’s listing at ₹135 versus the ₹126 issue price translated into a 7.14% listing gain in the table provided, giving investors an immediate price reference against the offer price. Post-listing, the dataset’s later snapshots highlighted price movement and volatility with a cited 52-week range of ₹93.30 to ₹154.40, underscoring how pricing can change well beyond listing day.

Conclusion

Amanta Healthcare’s ₹126 crore main-board IPO combined a fresh-issue fundraise with a clearly stated capex plan for new manufacturing lines at its Gujarat facility. The offering ran from September 1 to September 3, 2025, was allotted on September 4, and listed on September 9 at ₹135 against an issue price of ₹126. The next key dates investors typically track after listing, based on the provided information, include anchor lock-in expiries on October 3, 2025 and December 2, 2025, alongside company disclosures on project execution and utilisation of proceeds.